Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2007
01/25/2007WO2007009682A1 Oral pharmaceutical formulations comprising substituted pyrazoline compounds
01/25/2007WO2007009681A1 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES
01/25/2007WO2007009670A1 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof
01/25/2007WO2007009662A1 Substituted piperidine derivatives as somatostatin sst1 receptor antagonists
01/25/2007WO2007009657A1 Novel use of organic compounds
01/25/2007WO2007009655A1 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic
01/25/2007WO2007009635A1 Phenyl substituted piperazine-derivatives as inhibitors of plaminogenic activator inhibitors-i (pai-i)
01/25/2007WO2007009607A1 Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
01/25/2007WO2007009601A1 Novel stabilized carotenoid compositions
01/25/2007WO2007009578A1 Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes
01/25/2007WO2007009539A2 Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
01/25/2007WO2007009524A1 2-arylbenzothiazoles and uses thereof
01/25/2007WO2007009485A1 Substituted 8-phenoxy-y-carboline derivatives with 5ht1 activity
01/25/2007WO2007009462A2 Treatment of migraine and headaches
01/25/2007WO2007009397A1 Use of cymipristones for treating aids
01/25/2007WO2007009395A1 Schisandrin b preparation
01/25/2007WO2007009393A1 The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells
01/25/2007WO2007009392A1 The use of chlorogenic acid in the manufacturing medicaments for treating and/or preventing hepatic injury
01/25/2007WO2007009388A1 Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions and the use thereof
01/25/2007WO2007009355A1 Paclitaxel injection and preparation method thereof
01/25/2007WO2007009354A1 Pyrrolidine derivative intermediates,preparation and usage thereof
01/25/2007WO2007009353A1 Substituted thiazol-4-one compounds, preparation methods and use thereof
01/25/2007WO2007009326A1 A self-assembled and bistable quantum wire array of nano-medicine and its preparation process
01/25/2007WO2007009320A1 A preparation of statins for prolonged release
01/25/2007WO2007009265A1 NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS
01/25/2007WO2007009264A1 Chemotherapeutic agents for inhibition of protein translation
01/25/2007WO2007009245A1 Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
01/25/2007WO2007009236A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
01/25/2007WO2007009229A1 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
01/25/2007WO2007009227A1 Hepatitis c inhibitor peptide analogs
01/25/2007WO2007009201A2 Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis
01/25/2007WO2007009187A1 Polyphenol and probiotic containing nutritional supplement
01/25/2007WO2007009164A1 Method of particle formation
01/25/2007WO2007009146A1 Substituted 1-phenyl imidazoles as cox-i inhibitors
01/25/2007WO2006131303A3 Peptide deformylase (pdf) inhibitors 4
01/25/2007WO2006130080A3 Quinoline derivatives as nk3 anatgonists
01/25/2007WO2006128885A3 Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
01/25/2007WO2006127368A3 Methods for synthesizing imidazotriazinones
01/25/2007WO2006126082A3 Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
01/25/2007WO2006125977A3 Hybrid interfering rna
01/25/2007WO2006125642B1 Methods and apparatus for transdermal or transmucosal application of testosterone
01/25/2007WO2006124863A3 Pyrrolopyridine derivatives as protein kinase inhibitors
01/25/2007WO2006122986A3 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
01/25/2007WO2006122408A9 Bir domain binding compounds
01/25/2007WO2006122254A3 Stable micronized candesartan cilexetil and methods for preparing thereof
01/25/2007WO2006121861A3 Biphenylazetidinone cholesterol absorption inhibitors
01/25/2007WO2006121467A3 Tetrahydrocarbazole derivatives for treating flaviridae viruses
01/25/2007WO2006120682A3 Compositions and methods for treating hyperproliferative epidermal diseases
01/25/2007WO2006119168A3 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
01/25/2007WO2006117696A3 Diastereoisomers of 4-hydroxyisoleucine and uses thereof
01/25/2007WO2006117516A3 Topical compositions
01/25/2007WO2006117400A3 Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
01/25/2007WO2006114676A3 A process for the preparation of rupatadine
01/25/2007WO2006113864A3 Oxindole compounds and their uses as therapeutic agents
01/25/2007WO2006112961A3 Synergistic salivation components
01/25/2007WO2006110654A8 Spiroheterocyclic compounds and their uses as therapeutic agents
01/25/2007WO2006110607A8 Methods for treating infectious disease exacerbated asthma
01/25/2007WO2006110176A3 Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
01/25/2007WO2006108430A8 Nutrient composition comprising green tea polyphenols for treating osteosarcoma
01/25/2007WO2006105112A3 Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
01/25/2007WO2006102494A3 Nanoparticulate corticosteroid and antihistamine formulations
01/25/2007WO2006102345A3 Methods and systems for operating an aerosol generator
01/25/2007WO2006101745A3 Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
01/25/2007WO2006096285A3 Compositions and methods for treating or preventing flaviviridae infections
01/25/2007WO2006093774B1 Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
01/25/2007WO2006090376A3 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
01/25/2007WO2006089298A3 Pyrimidine-fused diazepine derivatives and indole-fused pteridines
01/25/2007WO2006086358A3 Mitotic kinesin inhibitors
01/25/2007WO2006085144A3 Compositions containing high omega-3 and low saturated fatty acid levels
01/25/2007WO2006084030A3 Small-molecule hsp90 inhibitors
01/25/2007WO2006083949A3 Sepsis prevention through adenosine receptor modulation
01/25/2007WO2006083869A3 Tumor necrosis factor inhibitors
01/25/2007WO2006078948A3 Stable pharmaceutical formulations of zonisamide and methods for their manufacture
01/25/2007WO2006078414A3 METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
01/25/2007WO2006074330A3 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
01/25/2007WO2006069805A3 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
01/25/2007WO2006066200A3 Solid forms of a chemokine receptor antagonist and methods of use thereof
01/25/2007WO2006065277A3 Heterocyclic aspartyl protease inhibitors
01/25/2007WO2006061428A3 Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
01/25/2007WO2006054304A3 Use of lipid conjugates in the treatment of disease
01/25/2007WO2006050921A3 Preparation of telmisartan salts with improved solubility
01/25/2007WO2006041874A3 Compounds for alzheimer's disease
01/25/2007WO2006039212A3 Substituted 2h-1,3-benzoxazin-4(3h)-ones
01/25/2007WO2006037016A3 Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
01/25/2007WO2006033005A3 Thrombopoietin receptor agonists
01/25/2007WO2006031799A3 Compositions comprising ubiquinones
01/25/2007WO2006017545A3 Systems and methods for inhibiting metastasis
01/25/2007WO2006015171A3 Use of glycosoaminoglycans for the prevention and treatment of sepsis
01/25/2007WO2005123128A3 Methods for treating conditions associated with masp-2 dependent complement activation
01/25/2007WO2005118777A8 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins
01/25/2007WO2005102333A9 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
01/25/2007WO2005097125A3 Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
01/25/2007WO2005090336A8 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands
01/25/2007WO2005065079A3 Medical implants and fibrosis-inducing agents
01/25/2007WO2005025556A3 Antibiotic cycloalkyltetrahydroquinoline derivatives
01/25/2007WO2004047844A8 Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
01/25/2007US20070021619 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
01/25/2007US20070021618 Crystal structure; hydrates; dissolvin gin solution; adding base; crystallization; salt formation
01/25/2007US20070021617 Crystal structure; hydrates; dissolving in solution; adding base; crystallization; salt formation
01/25/2007US20070021616 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation